GuidelineBritish journal of cancer2018
Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK.
Guideline in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Role of adjuvant chemotherapy in stage IC ovarian granulosa cell tumors: a systematic review and meta-analysis.Journal of gynecologic oncology · 2025Pooled it
- Physical exercise in patients with testicular cancer treated with bleomycin, etoposide and cisplatin chemotherapy: pulmonary and vascular endothelial function-an exploratory analysis.Journal of cancer research and clinical oncology · 2023Trial
- The role of alveolar epithelial junctions in early lung injury and COVID-19-induced fibrosis.Histochemistry and cell biology · 2026Article
- Radiological and Biochemical Diagnosis of a Primary Mediastinal Germ Cell Tumour: A Case Report.Cureus · 2026Article
- Longitudinal plasma and urinary SP-D and sRAGE during BEP chemotherapy in germ cell tumours.Frontiers in immunology · 2026Article
- Toxicity of BEP chemotherapy in germ cell tumors: focus on immune-mediated bleomycin pulmonary toxicity in comparison with EP and VIP regimens.Frontiers in immunology · 2026Review
- Systemic Chemotherapy in Penile Squamous Cell Carcinoma: Mechanisms, Clinical Applications, and Evidence-Based Regimens.Cancers · 2025Review
- Anticancer compounds from Streptomyces: insights from metagenomics and mechanistic perspective.Folia microbiologica · 2025Review
- Lymphocyte-Associated Inflammation Markers Predict Bleomycin-Induced Pulmonary Toxicity in Testicular Cancer.Journal of clinical medicine · 2025Article
- LINC00470 promotes malignant progression of testicular germ cell tumors.Molecular biology reports · 2024Article
- ROS-mediated lysosomal membrane permeabilization and autophagy inhibition regulate bleomycin-induced cellular senescence.Autophagy · 2024Article
- Mechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches.Cell biochemistry and biophysics · 2024Review
- Bortezomib restrains M2 polarization and reduces CXCL16-associated CXCR6Molecular medicine (Cambridge, Mass.) · 2024Article
- Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
- Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy.Frontiers in oncology · 2023Article
- Testicular cancer survivorship: Long-term toxicity and management.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Review
- Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era.Cureus · 2022Article
- Review
- Use of electrochemotherapy in a combined surgical treatment of local recurrence of rectal cancer.Journal of surgical case reports · 2021Article
- [Management of chemotherapy side effects and their long-term sequelae].Der Urologe. Ausg. A · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bleomycin, a cytotoxic chemotherapy agent, forms a key component of curative regimens for lymphoma and germ cell tumours. It can be associated with severe toxicity, long-term complications and even death in extreme cases. There is a lack of evidence or consensus on how to prevent and monitor bleomycin toxicity. We surveyed 63 germ cell cancer physicians from 32 cancer centres across the UK to understand their approach to using bleomycin. Subsequent guideline development was based upon current practice, best available published evidence and expert consensus. We observed heterogeneity in practice in the following areas: monitoring; route of administration; contraindications to use; baseline and follow-up investigations performed, and advice given to patients. A best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours has been developed and includes recommendations regarding baseline investigations, the use of pulmonary function tests, route of administration, monitoring and patient advice. It is likely that existing heterogeneity in clinical practice of bleomycin prescribing has significant economic, safety and patient experience implications. The development of an evidence-based consensus guideline was supported by 93% of survey participants and aims to address these issues and homogenise practice across the UK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.